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Abstract
Objective: The aim of this study was to confirm previous observations that proenkephalin A (PENK-A) may serve as prognostic
marker in the setting of acute ischemic stroke in a large stroke cohort. Methods: The plasma concentration of PENK-A was
measured within 72 hours of symptom onset in 320 consecutively enrolled patients with stroke. The primary outcome measures
were unfavorable functional outcome (modified Rankin Scale score 0-2 vs 3-6) and mortality within 90 days. Logistic and cox
proportional regression analyses were fitted to estimate odds ratios (ORs), hazard ratios (HRs) and 95% confidence intervals
(CIs), respectively, for the association between PENK-A and the primary outcome measures. Results: After adjusting for
demographic and vascular risk factors, PENK-A was neither independently associated with functional outcome (OR: 1.29, 95% CI:
0.16-10.35) nor mortality (HR: 1.02, 95% CI: 0.14-7.33).Conclusion: Among patients with acute stroke, PENK-A does not serve
as an independent prognostic marker in this external validation cohort.
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Introduction
Ischemic stroke is still one of the most challenging health-care
burdens globally.1,2 Stroke prognosis is dependent on stroke
severity, infarct location, stroke etiology, age, and comorbid-
ities. Accurate prediction is difficult, and incremental prognos-
tic information is needed to optimize risk stratification. A
deeper knowledge of novel factors associated with stroke out-
come is desirable. Accurately measured, externally validated
prognostic biomarkers are sparse.3 Several blood biomarkers
have been assessed, but only few have been validated in inde-
pendent studies. Among the most prominent are copeptin and
natriuretic peptides with an incremental prognostic value,4,5
but none of those has found its way into clinical routine.3
Proenkephalin A (PENK-A) is a stable precursor protein
fragment of the enkephalin (ENK) neuropeptide family.6 Enke-
phalin is involved in different biological pathways.7 In experi-
mental models, ENK reduces cerebral edema after ischemic
stroke pointing to a neuroprotective role.8 Proenkephalin A has
been shown to be a potent marker for blood–brain barrier integ-
rity.9 A product of the precursor peptide PENK-A is elevated in
patients with acute stroke and was associated with poor out-
come in intracranial hemorrhage (n ¼ 202) or subarachnoid
hemorrhage (SAH; n ¼ 360).10-12 Another study (n ¼ 189)
suggested that PENK-A plasma levels might serve as a good
prognostic marker in patients with acute stroke for unfavorable
outcome.13 Thus, a higher PENK-A plasma level might be
associated with poor clinical outcome in patients with acute
stroke.
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The aim of this study was to validate previous observations
of the predictive role of PENK-A in a larger cohort of patients




The design of the prospective cohort used in the present study
has been described in detail elsewhere.14 Initially, 605 patients
with suspected ischemic stroke presenting at the emergency
department of the University Hospital Basel in Switzerland
were screened. Ischemic stroke was defined according to the
World Health Organization criteria as an acute focal neurolo-
gical deficit lasting longer than 24 hours with no sign of acute
intracranial bleeding on cerebral imaging.15 Thus, the only
exclusion criteria for this study was evidence of intracranial
bleeding on initial imaging.14
Of these 605, 362 patients had an ischemic stroke, 359
completed follow-up (99.2%); and in 320 (89%) patients, ethy-
lenediaminetetraacetic acid (EDTA) plasma was available for
PENK-A measurement.
Standard Protocol Approvals, Registrations,
and Patients Consent
This study was approved by the local ethics committee and was
conducted according to the principles expressed in the Declara-
tion of Helsinki. From all patients, written informed consent
was obtained. This study reports on a trial of stroke blood
biomarkers (ClinicalTrials.gov: NCT00390962).
Clinical Baseline Variables and Diagnostic Work-Up
The following data were collected with a standardized bed-side
interview and complete chart review on admission: vital signs,
comorbidities as assessed by the Charlson Comorbidity Index
adjusted for stroke,16 medication prior to ischemic stroke, and
cardiovascular risk factors (ie, age, gender, smoking habits,
history of hypercholesterolemia, hypertension, diabetes melli-
tus, previous stroke, positive family history for myocardial
infarction, stroke, and history of coronary heart disease). Stroke
physicians prospectively recorded the National Institutes of
Health Stroke Scale score (NIHSS) upon admission.17 The
patients were clinically classified into 1 of the 4 subtypes of
the Oxfordshire Community Stroke Project classification,
which differentiate between lacunar stroke, partial and total
anterior circulation stroke (TACS), as well as posterior circula-
tion stroke (POCS).18 Stroke etiology was determined accord-
ing to the criteria of the Trial of Org 10172 in Acute Stroke
Treatment (TOAST) classification,19 which distinguishes
large-artery atherosclerosis, cardioembolism, small-artery
occlusion, other etiology, and undetermined etiology. Com-
puted tomography was performed in all patients on admission
to exclude intracranial hemorrhage. Additionally, magnetic
resonance imaging with diffusion-weighted imaging was
performed in 178 (56%) patients. The lesion size was categor-
ized into 3 different subtypes according to the volume in small
lesions (<10 mm3), medium lesions (10-100 mm3), and large
lesions (>100 mm3).20
Blood Sampling
In all patients, routine blood analyses were performed directly
upon admission including C-reactive protein (CRP), creatinine,
glucose, uric acid, cholesterol, triglycerides, and white blood
cells. In addition, serum and EDTA tubes were collected on
admission within 72 hours from symptom onset. These mate-
rials were directly centrifuged, aliquoted, and frozen at 80C
for future analyses.
Measurement of PENK-A. Plasma levels of PENK-A were mea-
sured in a batch blinded to clinical outcomes. In brief, a che-
moluminescence sandwich immunoassay detected midregional
PENK A 119-159 with monoclonal antibodies against aminoa-
cid sequence 121 to 134 as described previously (BRAHMS
GmbH, Henningsdorf, Germany).9 The intra-assay and inter-
assay coefficients of variations were <10% and <15%, respec-
tively. Median levels in healthy controls are 62.3 pmol/L
(range 41.8-131 pmol/L).9
Outcome Measures
Primary outcome measures were unfavorable functional out-
come defined as a modified Rankin Scale (mRS) score of >2
points and mortality of any cause. Trained stroke physicians or
study nurses assessed clinical outcome with a structured
follow-up telephone interview, 3 months after the acute stroke.
Interviewers were blinded to PENK-A levels and baseline clin-
ical variables.
Statistical Analysis
Discrete variables are expressed as frequency (percentage) and
the not normally distributed variables as medians with inter-
quartile ranges (IQR, 25th-75th percentiles). The distribution
of raw biomarker data was skewed. After log transformation
with a base of 10, the distribution of the biomarker data
approximated a normal distribution by plotting the data and
considering them visually. Analyses were done for both pri-
mary outcome measures separately. Two group comparisons
for categorical baseline measurements were performed by chi-
square test and for continuous, not normally distributed base-
line data by the Wilcoxon rank-sum test. Linear regression
analysis was performed for all interval-scaled variables.
To assess the independent association of PENK-A level with
functional outcome, logistic models with odds ratio (OR) and
95% confidence intervals (95% CI) were calculated. For mor-
tality, Cox regression models with hazard ratio (HR) were used.
Multivariate models were calculated to adjust for possible con-
founding factors. These final multivariate models included
variables significantly associated with an unfavorable outcome
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or mortality in the univariate analyses (ie, age, NIHSS on
admission, Charlson comorbidity index, heart failure, atrial
fibrillation, small artery disease, TACS, and POCS). A P value
< .05 was considered statistically significant. Finally, we con-
ducted univariate interaction analysis with the baseline charac-
teristics. The statistical analysis was performed with STATA
14.2 (StataCorp LLP, Texas).
Results
Study Population
The distribution of demographic and vascular risk factors
was not significantly different between the original cohort
of 359 patients and the 320 patients with available blood
samples.
The median age of the analyzed cohort of 320 patients was
75 years (IQR 65-82, in the original cohort 75 years [IQR 63-
83]), 41% (original cohort 41%) of the patients were women.
The most common cardiovascular risk factor was arterial
hypertension (76% of patients [original cohort 77%]). The
median NIHSS score on admission was 5 (IQR 2-10; original
cohort 5 [IQR 2-10]) and the median Charlson comorbidity
Index was 1 (IQR 0-2; Table 1). In our cohort, 20% of the
patients received an acute stroke treatment (intravenous throm-
bolysis or endovascular treatment).
Association of PENK-A Plasma Level With Baseline
Demographic and Vascular Risk Factors
Median PENK-A plasma level in women (158.5 pg/mL, IQR:
13.25-199.5) was significantly higher compared to median
PENK-A plasma level in men (139.0 pg/mL, IQR: 120-168;
P ¼ .0011). Plasma levels of PENK-A increased slightly with
age (r ¼ 0.27; P < .000) and were considerably higher in
octogenarians (165.75 pg/mL, IQR 131.0-206.0) compared to
nonoctogenarians (139.0 pg/mL, IQR: 120.0-165.5), P < .001.
In addition, there was a positive correlation between PENK-A
plasma levels and creatinine plasma levels (r ¼ 0.5; P ¼ .000),
as well as between PENK-A plasma level and uric acid (r ¼
0.31, P ¼ .000), but not with other laboratory parameters such
as CRP and glucose. We found a negative and very weak
correlation with body weight (r ¼ 0.01; P ¼ .048).
Median PENK-A plasma levels were higher in patients with
heart failure (184 pg/mL, IQR: 133.5-213.0) compared to
patients without heart failure (145.5 pg/mL, IQR: 120-
171.75; P ¼ .0004). The same was true for patients with atrial
fibrillation (165.5 pg/mL, IQR: 135.5-203.5) compared to
patients without atrial fibrillation (143.5 pg/mL, IQR 120-
174; P¼ .0007), as well as patients with coronary heart disease
(161 pg/mL, IQR: 132.5-203.5) compared to patients without
coronary heart disease (144.5 pg/mL, IQR: 119-172.5; P ¼
.0018).
There was neither a correlation between PENK-A plasma
levels and the NIHSS score on admission nor a correlation
between PENK-A plasma levels and diffusion weighted
imaging lesion size, both surrogate marker for stroke severity.
Finally, there was also no association with any of the TOAST
subgroups (Table 1).
Association of PENK-A With 90-Day Functional
Outcome and Mortality
Patient with an unfavorable outcome revealed significantly
higher median PENK-A plasma level (160.75 pg/mL, IQR:









Women, no. (%) 131 (41%) 149 (41%)
Age (median-IQR) 75 (62-82) 75 (63-83)
Medical history, n (%)
Hypertension, no. (%) 243 (76%) 275 (77%)
Arterial fibrillation, no. (%) 55 (17%) 75 (21%)
Coronary heart disease,
no. (%)
82 (26%) 91 (25%)
Heart failure, no. (%) 44 (14%)
Dyslipidemia, no. (%) 81 (25%) 93 (26%)
Diabetes mellitus, no. (%) 65 (20%) 71 (20%)
Current smoker, no. (%) 111 (35%) 124 (35%)
Previous cerebrovascular
event, no. (%)
79 (25%) 88 (25%)
Charlson comorbidity index,
no. (%)




5 (2-10) 5 (2-10)
MR imaging dataa




TACS 36 (11%) 41 (11%)
PACS 139 (44%) 162 (45%)
LACS 69 (22%) 74 (21%)
POCS 75 (23%) 83 (23%)
Laboratory values, median (IQR)
PENK-A (pg/mL) 147.75 (123.5-183.25)
CRP (mg/L) 3.5 (3-9.7) 3.6 (3.0-9.9)
Creatinine (mmol/L) 75 (63-88)
TOAST subtype, n (%)
Large-vessel disease 62 (19%) 65 (18%)
Cardioembolic 109 (34%) 131 (36%)
Small-artery disease 50 (16%) 55 (15%)
Other 16 (5%) 16 (4%)
Undetermined 83 (26%) 92 (26%)
Abbreviations: CRP, C-reactive protein; DWI, diffusion weighted imaging; IQR,
interquartile range; LACS, Lacunar anterior circulation stroke; MR, magnetic
resonance; NIHSS, National Institute of Health Stroke Scale; OCPS, Oxford-
shire Community Stroke Project score; PACS, partial anterior circulation
stroke; POCS, posterior circulation stroke; TACS, total anterior circulation
stroke; TOAST, Trial of Org 10172 in Acute Stroke Treatment Classification.
aDWI lesion size only for n ¼ 179 available.
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127.0-194.5) compared to patients with favorable outcome
(142.5 pg/mL, IQR: 120.0-166.0), P ¼ .0033.
In the univariate logistic regression analysis, patients
with a high PENK-A plasma level (OR 10.67, 95% CI:
2.31-49.38) were more likely to have an unfavorable out-
come (Table 2). But, after adjusting for all other significant
predictors of the univariate analysis, PENK-A levels were
no longer associated with functional outcome (Table 2).
Only age (OR 1.07, 95% CI: 1.04-1.10), NIHSS score on
admission (OR 1.16, 95% CI: 1.10-1.23), and Charlson
comorbidity index score (OR 1.39, 95% CI: 1.14-1.72)
remained independently associated with functional outcome
after adjustment (Table 2).
Similar results are found for mortality as the other primary
outcome measures. In this cohort, a total of 39 patients died
within 90 days after the stroke event. Median PENK-A plasma
level of these patients (160.0 pg/mL, IQR: 127.0-202.0) was
higher compared to the median PENK-A plasma level of the
survivors but not statistically significant (146 pg/mL, IQR:
123.0-181.5; P ¼ .069). The univariate cox regression model
for mortality showed a significant association for high PENK-A
plasma level with mortality (HR 8.61, 95%CI: 1.61-45.7; Table
3). In the multivariate analysis, only age (HR 1.07, 95% CI:
1.03-1.11) and NIHSS score on admission (HR 1.11, 95% CI:
1.07-1.16) remained independently associated with mortality
within 90 days after stroke.
We found no interaction of PENK-A levels regarding func-
tional outcome with age (p for interaction [pi] ¼ 0.81), gender
(pi ¼ 0.78), heart failure (pi ¼ 0.24), atrial fibrillation (pi ¼
0.63), renal insufficiency (pi ¼ 0.13), or acute stroke treatment
Table 2. Significant Univariate and Multivariate Logistic Regression Analysis for Functional Outcome.a,b
Logistic Regression Model Univariate Analyses Multivariate Analyses
Predictors OR 95% CI P OR 95% CI P
Log PENK-A (pg/mL)c 10.67 2.31-49.38 .002 1.95 0.27-13.72 .50
Log CRP (mg/L)c 3.00 1.72-5.25 <.001
Age (years) 1.06 1.04-1.09 <.001 1.07 1.04-1.10 <.001
NIHSS score 1.16 1.11-1.21 <.001 1.16 1.10-1.23 <.001
Charlson index score 1.38 1.17 - 1.61 <.001 1.39 1.14-1.72 .001
Atrial fibrillation 2.07 1.15-3.73 .015 0.57 0.25-1.31 .19
DWI lesion size (mm3)d 2.51 1.49-4.24 .001
Heart failure 2.56 1.15-3.73 .005 1.30 0.56-3.04 .54
Small-artery disease 0.44 0.22-0.86 .017 0.87 0.37-2.04 .75
Undetermined 1.7 1.02-2.82 .039 1.20 0.60-2.41 .60
TACS 0.51 0.29-0.9 .02 2.22 0.77-6.41 .14
POCS 0.6 0.47-0.77 <.001 0.84 0.41-1.72 .63
Abbreviations: CI, confidence interval; CRP, C-reactive protein; DWI, diffusion weighted imaging; HR, hazard ratio; NIHSS, National Institute of Health Stroke
Scale; OR, odds ratio; PENK-A, proenkephalin A; POCS, posterior circulation stroke; TACS, total anterior circulation stroke.
aBecause date of CRP and DWI is only available in a subgroup of patients, these parameters were not included in the final multivariate analysis.
bCRP (n ¼ 262).
cLog10-transformed values were used in these analyses.
dDWI, diffusion weighted imaging (n ¼ 179).
Note: The boldface values will highlight that this values are statistically significant values.
Table 3. Significant Univariate and Multivariate Cox Regression
Model for Mortality.
Cox Regression
Model Univariate Analyses Multivariate Analyses
Predictors HR 95% CI P HR 95% CI P
Log PENK-A
(pg/mL)a,b,c
8.61 1.61-45.7 .012 1.02 0.14-7.33 .98
Log CRP (mg/L)a,b,c 2.85 1.62-5.02 <.001
Age (years) 1.08 1.05-1.13 <.001 1.07 1.03-1.11 <.01








Heart failure 2.38 1.16-4.89 .018 2.97 1.33-6.64 .08
Small-artery
disease
0.13 0.02-0.97 .047 0.28 0.04-2.12 .22
Undetermined 1.89 0.99-3.6 .052
TACS 5.44 2.83-10.47 <.001 2.09 0.98-4.49 .057
POCS 0.36 0.13-0.99 .05 0.73 0.24-2.18 .57
Abbreviations: CI, confidence interval; CRP, C-reactive protein; DWI, diffusion
weighted imaging; HR, hazard ratio; NIHSS, National Institute of Health Stroke
Scale; PENK-A, proenkephalin A; POCS, posterior circulation stroke; TACS,
total anterior circulation stroke; OR, odds ratio.
aBecause of numerical imbalance CRP and DWI were not included in the final
multivariate analysis.
bCRP (n ¼ 262).
cLog10-transformed values were used in these analyses.
dDWI (n ¼ 179).
Note: The boldface values will highlight that this values are statistically signif-
icant values.
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(pi¼ 0.59); or PENK-A levels regarding mortality with age (pi
¼ 0.55); gender (pi ¼ 0.06), heart failure (pi ¼ 0.14), atrial
fibrillation (pi ¼ 0.83), renal insufficiency (pi ¼ 0.44) or acute
stroke treatment (pi ¼ 0.11).
Discussion
This study of 320 patients with acute stroke could not confirm
and validate that PENK-A plasma levels were independently
associated with functional outcome or mortality within 90 days
after index stroke. We found no incremental value of PENK-A
as prognostic marker in the acute stroke setting. The initial
association of PENK-A levels with functional outcome and
mortality was attenuated and most likely confounded by other
comorbidities.
So far, there has been one promising study looking at
PENK-A levels and stroke outcome, in which high PENK-A
plasma levels were significantly and independently associated
with an unfavorable functional outcome and mortality in
patients with acute stroke.13
In addition, there is evidence from studies in patients
with other cerebrovascular diseases such as spontaneous
intra-cerebral hemorrhage or SAH, which showed that high
PENK-A plasma levels were independently associated with
unfavorable outcome.10-12 In contrast, in the unadjusted
analyses, we only found an association of PENK-A levels
with an unfavorable outcome (mRS > 2), suggesting that the
association was confounded by demographic and other vas-
cular risk factors. Compared to the above-mentioned smaller
study (n ¼ 124),13 the current study analyzed almost 2.5
times as many patients (n ¼ 320). Due to potentially insuf-
ficient power, the positive result in other studies may not
reflect a real-independent pathophysiological impact of
PENK-A in acute stroke. In addition, we used more vari-
ables for adjustment in our model such as comorbidities
reflected by the Charlson comorbidity index, stroke etiol-
ogy, and stroke syndrome.
Additionally, we could not confirm a direct correlation of
stroke lesion volume and PENK-A levels as has been shown by
others.13 This challenges the assumption that PENK-A levels
are related to blood–brain barrier leakage.9,13
Presumably, this contradictory finding may be partially
explained by the fact that ENKs are not only specifically
expressed in central neuronal tissue but also expressed in
the peripheral neuronal tissue of gastrointestinal tract or the
lung, the heart, the skeletal muscle, the kidney, and immune
cells.21-23 Furthermore, the biological role of this neuropeptide
family is not fully understood; they are involved in many dif-
ferent pathways such as immune stimulation, nociception, or
stress response,9 thus not specific to ischemic tissue damage
during acute stroke.
Our results demonstrate a close association between
PENK-A level and cardiac comorbidities. Higher PENK-A
plasma level was found in patients with heart failure, atrial
fibrillation, or coronary heart diseases. These findings are con-
sistent with previous studies reporting that high PENK-A levels
predict a poor outcome in patients with acute myocardial
infarction. In addition, high PENK-A plasma level may be also
associated with unfavorable course of heart failure.24,25 This
may be related to the fact that cardiomyocytes produce ENKs
which influence blood pressure and heart rate.26 Since blood
pressure and cardiac activity are usually increased in acute
ischemic stroke, higher PENK-A plasma level may be partially
explained by this cardiac ENK effect. But, there was no sig-
nificant association to the cardioembolic subtype according to
the TOAST classification. Thus, PENK-A is not suitable to
discriminate stroke subtypes. We hypothesize that the missing
association of PENK-A levels with specifically cardioembolic
stroke etiology despite the link with underlying cardiac comor-
bidities is due to the fact that probably other factors such as
renal insufficiency influence PENK-A levels even more pro-
nounced. Moreover, we found that age is a strong confounder
but revealed no interaction.
In our multivariate analyses, NIHSS, age, as well as the
Charlson comorbidity index for functional outcome remained
the most relevant independent prognostic factors for functional
outcome and mortality in patients with acute stroke. This is
inline with several outcome prediction studies as well as vali-
dated clinical prognostic scores, suggesting that our cohort
seems to be representative of patients with ischemic
stroke.27-30
Despite our relatively large sample size and representa-
tive stroke population, some limitations merit attention.
First, PENK-A was not a prespecified marker in this cohort
study but analyzed post hoc. Second due to single measure-
ment within 72 hours (with 89% within 24 hours) from
stroke onset, the current analyses provide no information
on the kinetics of PENK-A after stroke. Therefore, we can-
not draw any conclusions about the prognostic role beyond
72 hours of stroke onset. However, it is debatable if prog-
nostic information for risk stratification after 72 hours of
stroke onset is clinically relevant.
Conclusion
In this study, PENK-A failed to be an independent prognostic
biomarker for unfavorable outcome or mortality among
patients with acute ischemic stroke. This result may be related
to the fact that PENK-A is not organospecific and is involved in
different pathways and may be strongly influenced by other
known vascular risk factors, thus not able to add incremental
value for stroke risk stratification beyond the NIHSS and age.
This study underlines the relevance of external validation, as
blood biomarkers typically report higher effect size in pilot
studies compared to subsequent larger validation studies of the
same biomarker.27
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